One of the biggest myths regarding the proposed International Pricing Index Model is that it will have little to no effect on biomedical research and development (R&D). In fact, a recent survey of PhRMA member companies found many expect the proposal to greatly affect their R&D. Download this infographic for some of the key findings from survey respondents.